+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Uveitis Treatment Market, by Drug Class, by Disease Type, by Distribution Channel, by Country, Industry Analysis and Forecast, 2019 - 2025

  • ID: 5017732
  • Report
  • March 2020
  • Region: Europe
  • 90 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
The Europe Uveitis Treatment Market is expected to witness market growth of 5.02% CAGR during the forecast period (2019-2025).

For the treatment of infectious uveitis, certain medications have advantages over others. Topical and systemic treatments are often used in the treatment of ocular infection, but the treatment route may be limited by penetration, concentration, and duration. The advent of antimicrobial intravitreal therapy has furthered the treatment of intraocular infections. With limited systemic absorption, being able to overcome blood-ocular barriers allows for large concentrations of drugs to be administered directly to the posterior section. Nevertheless, because the difference between the therapeutic and toxic doses of certain antimicrobial drugs falls within a small range of concentration, intravitreal therapy can be associated with risks of ocular toxicity.

Intermediate uveitis is a vitreous and peripheral retina-localized type of uveitis. Primary inflammatory sites include the vitreous which includes other entities such as pars planitis, posterior cyclitis, and hyalitis. Intermediate uveitis may be either an isolated eye disease or related to the development of a systemic condition such as multiple sclerosis or sarcoidosis. As such, the first manifestation of a systemic disorder may be intermediate uveitis. Infectious causes of intermediate uveitis include infection with the Epstein-Barr virus, Lyme disease, HTLV-1 virus, cat scratch disease, and hepatitis C.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Scope of the Study

Market Segmentation:

By Drug Class
  • Anti-inflammatory
  • Immunotherapy & Targeted Therapies
  • Antimicrobial Drugs
  • Other Drug Class
By Disease Type
  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online stores
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Uveitis Treatment Market, by Drug Class
1.4.2 Europe Uveitis Treatment Market, by Disease Type
1.4.3 Europe Uveitis Treatment Market, by Distribution Channel
1.4.4 Europe Uveitis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Europe Uveitis Treatment Market by Drug Class
3.1 Europe Anti-inflammatory Market by Country
3.2 Europe Immunotherapy & Targeted Therapies Market by Country
3.3 Europe Antimicrobial Drugs Market by Country
3.4 Europe Other Drug Class Market by Country

Chapter 4. Europe Uveitis Treatment Market by Disease Type
4.1 Europe Anterior Uveitis Market by Country
4.2 Europe Posterior Uveitis Market by Country
4.3 Europe Intermediate Uveitis Market by Country
4.4 Europe Other Diseases Market by Country

Chapter 5. Europe Uveitis Treatment Market by Distribution Channel
5.1 Europe Hospital Pharmacies Market by Country
5.2 Europe Retail Pharmacies Market by Country
5.3 Europe Online stores Market by Country

Chapter 6. Europe Uveitis Treatment Market by Country
6.1 Germany Uveitis Treatment Market
6.1.1 Germany Uveitis Treatment Market by Drug Class
6.1.2 Germany Uveitis Treatment Market by Disease Type
6.1.3 Germany Uveitis Treatment Market by Distribution Channel
6.2 UK Uveitis Treatment Market
6.2.1 UK Uveitis Treatment Market by Drug Class
6.2.2 UK Uveitis Treatment Market by Disease Type
6.2.3 UK Uveitis Treatment Market by Distribution Channel
6.3 France Uveitis Treatment Market
6.3.1 France Uveitis Treatment Market by Drug Class
6.3.2 France Uveitis Treatment Market by Disease Type
6.3.3 France Uveitis Treatment Market by Distribution Channel
6.4 Russia Uveitis Treatment Market
6.4.1 Russia Uveitis Treatment Market by Drug Class
6.4.2 Russia Uveitis Treatment Market by Disease Type
6.4.3 Russia Uveitis Treatment Market by Distribution Channel
6.5 Spain Uveitis Treatment Market
6.5.1 Spain Uveitis Treatment Market by Drug Class
6.5.2 Spain Uveitis Treatment Market by Disease Type
6.5.3 Spain Uveitis Treatment Market by Distribution Channel
6.6 Italy Uveitis Treatment Market
6.6.1 Italy Uveitis Treatment Market by Drug Class
6.6.2 Italy Uveitis Treatment Market by Disease Type
6.6.3 Italy Uveitis Treatment Market by Distribution Channel
6.7 Rest of Europe Uveitis Treatment Market
6.7.1 Rest of Europe Uveitis Treatment Market by Drug Class
6.7.2 Rest of Europe Uveitis Treatment Market by Disease Type
6.7.3 Rest of Europe Uveitis Treatment Market by Distribution Channel

Chapter 7. Company Profiles
7.1 AbbVie, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals:
7.2 Alimera Sciences, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.1 Recent strategies and developments:
7.2.1.1 Product Launches and Product Expansions:
7.3 Enzo Biochem, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Research & Development Expense
7.4.4 Recent strategies and developments:
7.4.4.1 Product Launches and Product Expansions:
7.4.4.2 Partnerships, Collaborations, and Agreements:
7.5 Bausch Health Companies, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Clearside Biomedical, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Research & Development Expense
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 EyePoint Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.7.5.2 Acquisition and Mergers:
7.8 Santen Pharmaceutical Co., Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Topivert Ltd.
7.9.1 Company Overview
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Recent strategies and developments:
7.10.4.1 Acquisition and Mergers:
7.10.4.2 Approvals:
7.10.5 Research & Development Expense
Note: Product cover images may vary from those shown
3 of 4
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll